EL PASO, TX--(Marketwired - January 22, 2014) - Premier Biomedical, Inc. (OTCQB: BIEI) today released the following statement regarding advances in the treatment of Head Trauma. There has been considerable news lately related to professional sports and the incidence rate of head trauma, also referred to as Traumatic Brain Injury, and its lasting effects on clinical depression, suicide/violence ideation, PTSD and longer term, persistent neurological diseases such as Parkinson's Disease, Alzheimer's Disease, and Amyotrophic Lateral Sclerosis (ALS). The scope of the problem is revealed by lesser known statistics published by the Veterans Administration, indicating suicide rates among active-duty personnel are almost one per day. If we include veterans, the number of suicides jumps to almost ONE PER HOUR. This is a huge morale problem and one that demands our collective utmost attention.
Premier Biomedical, Inc., (BIEI), reported that they have achieved a significant breakthrough in the laboratory with the assistance of their R&D partners, the University of Texas at El Paso (UTEP) and the Department of Defense (DOD) Center of Expertise at the William Beaumont Army Medical Center, in isolating and eliminating, from cerebral spinal fluid, the molecular compounds believed to be responsible for this over-arching neurological problem. Animal and clinical studies will be scheduled upon successful completion of initial laboratory studies.
Premier CEO, William A. Hartman, stated, "This is a huge development that could have far-reaching benefits for our military personnel and veterans as well as athletes in high school, college, and professional sports. We are also developing objective tests to accurately and objectively measure the intensity of the neurological problems as well as procedures to treat those people so afflicted. We have learned that such brain trauma is not necessarily induced by one major event, but by an accumulation of smaller, less noticeable events. To that end, we have upcoming near-term meetings with medical personnel from several of the major sports organizations to advise them how they can become involved with us in speeding our developments toward an available test and treatment for this prevalent injury."
About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, in collaboration with the University of Texas at El Paso and US Department of Defense, specifically targeting the treatment of Alzheimer's disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Blood Sepsis and Viremia, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier is headquartered in El Paso, Texas, with business offices in Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI." http://www.premierbiomedicalinc.com/
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.